[go: up one dir, main page]

UY29274A1 - PHARMACEUTICAL COMPOSITION TO TREAT HYPERTENSION, WHICH INCLUDES TELMISARTANE AND HYDROCLOROTIAZIDA - Google Patents

PHARMACEUTICAL COMPOSITION TO TREAT HYPERTENSION, WHICH INCLUDES TELMISARTANE AND HYDROCLOROTIAZIDA

Info

Publication number
UY29274A1
UY29274A1 UY29274A UY29274A UY29274A1 UY 29274 A1 UY29274 A1 UY 29274A1 UY 29274 A UY29274 A UY 29274A UY 29274 A UY29274 A UY 29274A UY 29274 A1 UY29274 A1 UY 29274A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
telmisartane
hydroclorotiazida
treat hypertension
hydrochlorothiazide
Prior art date
Application number
UY29274A
Other languages
Spanish (es)
Inventor
Peter Bohm
Axel Riedel
Helmut E Schumacher
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29274(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY29274A1 publication Critical patent/UY29274A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica que comprende aproximadamente 80 mg de telmisartano y aproximadamente 25 mg de hidroclorotiazida, o aproximadamente 160 mg de telmisartano y aproximadamente 50mg de hidroclorotiazida, para el tratamiento de la hipertensión en pacientes con una reducción de la tensión arterial insuficiente tras un tratamiento con un antagonista del receptor de angiotensina II, o una composición farmacéutica de un antagonista del receptor de angiotensina II y una dosis baja de hidroclorotiazida.A pharmaceutical composition comprising about 80 mg of telmisartan and about 25 mg of hydrochlorothiazide, or about 160 mg of telmisartan and about 50 mg of hydrochlorothiazide, for the treatment of hypertension in patients with insufficient blood pressure reduction after treatment with a angiotensin II receptor antagonist, or a pharmaceutical composition of an angiotensin II receptor antagonist and a low dose of hydrochlorothiazide.

UY29274A 2004-12-17 2005-12-20 PHARMACEUTICAL COMPOSITION TO TREAT HYPERTENSION, WHICH INCLUDES TELMISARTANE AND HYDROCLOROTIAZIDA UY29274A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17

Publications (1)

Publication Number Publication Date
UY29274A1 true UY29274A1 (en) 2006-07-31

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29274A UY29274A1 (en) 2004-12-17 2005-12-20 PHARMACEUTICAL COMPOSITION TO TREAT HYPERTENSION, WHICH INCLUDES TELMISARTANE AND HYDROCLOROTIAZIDA

Country Status (15)

Country Link
EP (1) EP1827424A1 (en)
JP (1) JP2008524136A (en)
KR (1) KR20070097511A (en)
CN (1) CN101080225A (en)
AR (1) AR052052A1 (en)
AU (1) AU2005315855A1 (en)
BR (1) BRPI0519656A2 (en)
CA (1) CA2589493A1 (en)
EA (1) EA200701159A1 (en)
IL (1) IL183944A0 (en)
NO (1) NO20072325L (en)
PE (1) PE20060768A1 (en)
TW (1) TW200637546A (en)
UY (1) UY29274A1 (en)
WO (1) WO2006063737A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
ES2406939T3 (en) † 2007-10-19 2013-06-10 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical solid matrix preparation
WO2009058950A2 (en) 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2009115301A1 (en) 2008-03-19 2009-09-24 Ratiopharm Gmbh Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
PE20110551A1 (en) * 2008-07-31 2011-09-02 Takeda Pharmaceutical SOLID PHARMACEUTICAL COMPOSITION CONTAINING A BENZIMIDAZOLE DERIVATIVE AND A DIURETIC
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2011002423A2 (en) * 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (en) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Solid dosage forms containing telmisartan.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk Multilayer tablet containing telmisartan and hydrochlorothiazide
WO2015012205A1 (en) * 2013-07-23 2015-01-29 第一三共株式会社 Medicine for preventing or treating hypertension
CN106562973A (en) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 Anti-hypertension medicine compound preparation
CN107501192A (en) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 The eutectic of Telmisartan and Hydrochioro
CN108653227A (en) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 A kind of Telmisartan hydrochlorothiazide tablets and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (en) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Elongated, divisible tablet
CA2472392C (en) * 2002-01-16 2009-07-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof

Also Published As

Publication number Publication date
TW200637546A (en) 2006-11-01
WO2006063737A1 (en) 2006-06-22
CN101080225A (en) 2007-11-28
PE20060768A1 (en) 2006-09-29
JP2008524136A (en) 2008-07-10
EA200701159A1 (en) 2007-12-28
CA2589493A1 (en) 2006-06-22
AR052052A1 (en) 2007-02-28
IL183944A0 (en) 2007-10-31
KR20070097511A (en) 2007-10-04
AU2005315855A1 (en) 2006-06-22
EP1827424A1 (en) 2007-09-05
NO20072325L (en) 2007-07-06
BRPI0519656A2 (en) 2009-03-03

Similar Documents

Publication Publication Date Title
UY29274A1 (en) PHARMACEUTICAL COMPOSITION TO TREAT HYPERTENSION, WHICH INCLUDES TELMISARTANE AND HYDROCLOROTIAZIDA
AR109605A2 (en) METHOD FOR TREATING PERIPHERAL VASCULAR DISEASES, COMPOSITION AND USE
ECSP099501A (en) FORMULATIONS OF UNIT DOSE AND METHODS FOR THE TREATMENT OF THROMBOSIS WITH AN ORAL INHIBITOR OF FACTOR XA
UY32177A (en) TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
ECSP045430A (en) COMBINATION THERAPY FOR CANCER TREATMENT
CO6150188A2 (en) USE OF TEENCTEPLASA TO TREAT AN ACUTE ISCHEMICAL ICTUS
CO6361942A2 (en) COMBINATION THERAPY WITH PEPTIDIC EPOXYCETONES
CR11724A (en) AGENT TO TREAT DISEASES
AR060306A1 (en) ANTIBODY COMBINATION THERAPY AGAINST CTLA4
EA201100814A1 (en) PHARMACEUTICAL FORMS OF APPLICATION CONTAINING NIFEDIPINE OR NIZOLDIPIN AND ANTAGONIST ANGIOTENZINE II AND / OR DIURETIC
CO6220969A2 (en) WEEKLY ADMINSITRATION OF DIPEPTIDILO PEPTIDASE INHIBITORS
AR033418A1 (en) PREPARED DETACHABLE MUCOADHESIVE PHARMACEUTICAL FOR THE ADMINISTRATION OF ACTIVE SUBSTANCE IN VETERINARY AND HUMAN MEDICINE
CL2011000798A1 (en) Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation.
AR054909A1 (en) MODULATION OF RECEPTORS ACTIVATED BY THE PEROXISOM PROLIFER
CL2011000625A1 (en) Solid preparation comprising 2-ethoxy-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1h-benzimidazole (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl carboxylate, a ph regulating agent and a calcium antagonist compound; and methods for using and improving dissolution of the compound in the solid preparation.
AR051968A1 (en) METHODS AND COMPOSITIONS THAT USE JNK INHIBITORS FOR THE TREATMENT AND MANAGEMENT OF CENTRAL NERVOUS SYSTEM INJURY
MX2009011900A (en) Diabetic wound healing.
ECSP078014A (en) DOSAGE REGIME FOR PRASUGREL
AR045783A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A P2X7 RECEIVER ANTAGONIST AND AN NON-STEROID ANTI-INFLAMMATORY DRUG
AR065139A1 (en) MEDICATION FOR THE TREATMENT OF ENDOMETRIOSIS
AR048370A1 (en) COMPOSITION TO IMPROVE COGNITIVE FUNCTIONS AND MEMORY
MX341660B (en) Ghrelin receptor agonist for treatment of dyscrasia.
PE20091885A1 (en) USE OF DRONEDARONE TO PREPARE A DRUG FOR THE TREATMENT OF PATIENTS WITH ARRHYTHMIA AND WHO HAVE AN INCREASED CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONE
CL2008003558A1 (en) Pharmaceutical composition comprising valrubicin and dimethyl sulfoxide in intravesical dosage form, useful for treating bladder cancer.
AR075866A1 (en) A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161005